Cassava Sciences Inc (SAVA) Share Price

And i might add, there are also these silly court cases that describe how the higher ups at Cassava deliberately cheated on the ph1 and ph2 data.
Now multiplex these premises and come to your own conclusion....

Its very similar to IBRX in regards to the short situation. When they stay around for years and short interest consistently stays above 30% they are usually very smart people with high conviction. I wouldnt want to be the counterparty.
A lot of people forget that a lot of smart people in bioland make fortunes on the short side... Its not for me as im not one of the smart people but man have i scratched my head when analyzing the opportunites.

Compare volume on the rise vs rinse
Readying for the fraudulent readout is my guess.

Perhaps because of this.
https://www.collins.senate.gov/newsroom/senators-collins-cortez-masto-kaine-capito-bill-to-expand-alzheimers-care-and-prevention-efforts-to-be-signed-into-law

Exactly and was much below that the 1st time I went in. No reason to give back huge gains from a gamble at 30 bucks. I wish those luck that do and hope it hits for all who suffer but no way I gamble from 30 bucks. GLTA

"which is why I wouldn't buy in unless price was much, much lower"
It was much lower, below 10 bucks mid July this year.

Well, P3 outcome is expected before the end of the year. Will it be positive? Seems to be difference of opinion on this board.

Is positive news expected soon?

Forgot to mention - it is also up in AH trading on almost 50K volume. Very unusual. Somebody knows something.

Well, I can't tell, but the run was different than daily oscillations during several past months. It was basically up or flat all day, not typical for day trading. Possibly small short squeeze or slow leak.

Why did it run today? Thx

Quite the run indeed after more than $2 drop the previous day. No news? How about a small leak from Pentara?

I suggest you check the facts before making wrong statements. Several people on the board of directors made huge cash purchases. Look it up. Seems to me you are here to bash the stock. Well, we will see in about 2 to 3 weeks.

This is not your any day type of run this is a slow leak type of run. I expect SAVA to increase 5-15% daily as it leads into their Ph3 data release! Given the recent two new hires from Pfizer and Biogen it's a safe bet that the data is positive and stat sig. In my opinion, the share price day of data release will easily surpass the all time high of $131.

As it started to run, more and more shorts might be trying to cover, which has then enhanced the run. JMHO

Quite the run on no news

No news. The pump is due to Big Call options buys.

Read my previous posts over the years for substance. They all fail to meet robust expectations. It's the nature of the beast. I give these guys as good a shot as any...which is a long shot IMO

talk substance please
it sounds like you have a hunch about bad data too?

Nope. Never drank it. Made many bags though. Odds are the trial is unsuccessful like all the rest which is why I wouldn't buy in unless price was much, much lower. That said I'm excited to see the results in the next month or so and hope for the best. Shorts could be in for some real trouble in the event results turn out positive regardless of the odds. Jmho

are you drinking the kool aid or pushing the agenda?
Data will matter in the end and they went above and beyond to cheat on the ph2...
The insider buying on this is a non-factor.

I don't need to compare the two. I know how many have been bought the last few years. More than any company I follow.

Insider buying? not a single share bought in 2024....
compare shares bought vs free shares gifted via options/salary paid.
ALL the cons have insiders with many shares..... it helps you sell more and more shares to the public.

"Lindsay H. Burns, a senior vice president of the pharmaceutical company Cassava Sciences[2] until July 2024 and married to its CEO Remi Barbier."

This is the woman that said they DO in fact skew the control group too....

https://www.beingpatient.com/cassava-sciences-fraud-indictment-settled/#:~:text=On%20September%2026th%2C%20Cassava%20Sciences,for%20Cassava's%20experimental%20Alzheimer's%20drug shes too far gone........ an accomplice

Actually there has been more insider buying on this one than most alternative AD plays. I bet you can't find one with more

What i believe they did is select the patients for their ph1 and ph2 "very carefully" aka include the best results and disregard the rest. Then there was this Dr. Wang story that hints at many bodies in the basement. And then there was ridiculous manipulation of the endpoints they wanted to achieve....
They should take this one as a great "learning case" for the statisticians.

Now what I am trying to say is that they wont be able to do that for a ph3 trial.

check the all time chart.... the shares these people "havent sold" are free options..... not really skin in the game nor indicative of conviction.
They would never sell those free shares....... What they do enjoy is selling shares to the public and pay themselves a fat salary.
What is remarkable is that this company isnt some junky low floater...

Scamming investors itself is highly unethical... But they can likely always cushion the loss. Deliberately lying to patients too to make them participate in a trial for a grave disease they suffer from........ getting their hopes up........ all while knowing you have NOTHING for them. That is the real crime. Remy and his gang are sociopaths brazen enough to do it big...

That remains to be seen. You could be dead wrong here. Insiders haven't sold a single share, institutional holdings are increasing, and SAVA just hired a new Chief Commercial Officer. Apparently, they are very confident. Sure, the data is blinded at this point, but they have feedback from testing sites doctors and patients.

expecting 5-10$ here soon
Aint no way to skew a ph3.....
What will beat their results in terms of cognitive function? Stretching? Taking a walk in the park?

Appreciate the reference!

OK...a little short but not very.

YouTube Sava Clarity has posted some interesting projections this morning.

Less than 40 days until expected quite positive news.

5’10”

Are you short?

Expecting huge Christmas present December 23 before the market opens.

post ph3 readout? 5$? 10$?
Time for crooked Remi to show us the hand. I wouldnt be surprised to learn this is another Theranos. How do you window dress a ph3 data set? It will be pretty hard for them. No position.

SAVA, 10Q 11/7

8:30 AM on November 7--will Rick provide an important update on SAVA FDA progress????
Expect short sellers could have a bad week post election for several reasons. Seat belts on...

Simufilam, an experimental drug for Alzheimer's disease, interacts with amyloid beta (Aß) through its mechanism involving filamin A (FLNA). Here are the key points regarding its relationship with amyloid:
Mechanism of Action
Binding to Filamin A: Simufilam binds to an altered form of filamin A, which is implicated in Alzheimer's pathology. This binding disrupts the interaction between FLNA and the a7 nicotinic acetylcholine receptor (a7nAChR), a pathway that is activated by soluble Aß42 and leads to neurodegeneration through tau hyperphosphorylation.
Effects on Amyloid Beta
Reduction of Aß42 Binding: Research indicates that simufilam significantly reduces the binding affinity of Aß42 to a7nAChR. It has been shown to decrease this binding with a potency measured at 10 picomolar IC50, effectively disrupting the toxic signaling associated with amyloid.
Disruption of Toxic Signaling: By interfering with the FLNA-a7nAChR linkage that is critical for amyloid's toxic effects, simufilam may help mitigate the neurotoxic consequences of amyloid accumulation in the brain.
Impact on Inflammation and Neurodegeneration
Anti-inflammatory Effects: Simufilam has also been shown to reduce inflammatory cytokine release from Aß42-stimulated human astrocytes, suggesting it may have anti-inflammatory properties that further support brain health.
Neuroprotective Potential: In animal models, simufilam has been reported to reduce tau hyperphosphorylation and amyloid deposition, indicating a potential neuroprotective effect against the pathological features of Alzheimer's disease.
Conclusion
Simufilam's approach to modulating the interactions between amyloid beta and cellular receptors represents a novel strategy in Alzheimer's therapy. By targeting these interactions, it aims to disrupt toxic signaling pathways associated with amyloid accumulation, potentially offering a new avenue for treatment in Alzheimer's disease.

For a disease no one knows the cause of....no

Have you ever use it? Try, you may learn something. It does biostatistical calc very well. Try Perplexity.ai
You feed it P2 results and P3 sample size and ask to calculate p, probability of stat. sig., etc.

Artificial, yes.

Intelligence? Not so much.

AI simulations? Lol

Sixty bucks before the Rethink readout?
The general consensus is that a run-up rally is about to start. Being short now, knowing that the share price is likely to double in the next 45 to 60 days, is a losing proposition.
If I were short and believed in a Phase 3 failure, I would exit my position now, stop paying interest, and short at twice the price just before the readout.
Of course, the shorts are entrenched in their positions and beliefs and may not do what they should.
The probability of a statistically significant Rethink readout is estimated at 65% based on a very conservative trial design, 80% for Refocus, and 93% for the combined Rethink and Refocus trials. According to AI simulations, this probability ranges from 95% to 98%.
Considering these facts, $60 before the readout seems low given the risk/reward potential.

Let me add that insiders haven't sold a single share. If there were a problem with the Phase 2 trial data, Remi wouldn't hold his 2 mil. shares. He was involved in the process and knows best.

Talk to the families of patients in the trials-the best due diligence available

43.3% short cost to borrow over 100% now

Um, I don't think you understand how shorting works.

Shorts keep borrowing shares and shorting more - over 50% of the float not counting phantom shares and synthetic short positions. Totally insane.

Last Patient, Last Visit is an expected milestone. Always appreciated as material information. Squeeze? No.